7 documents

Read All
19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies suggest inhibiting adenosine kinase, DCK or SLC29A1 could help treat Staphylococcus aureus infection. Screening of a CRISPR single-guide RNA (sgRNA) library in a human lung lymphoblast cell line expressing CRISPR-associated protein...
Read More
07:00 , Jun 25, 2015 |  BC Innovations  |  Product R&D

Cellectis' UCART-ography

A year after Pfizer Inc. threw its weight behind Cellectis S.A.'s chimeric antigen receptor (CAR) T cell platform, the biotech has signed a three-year partnership with Weill Cornell Medical College to test whether its system...
Read More
07:00 , Apr 30, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Deoxycytidine kinase (DCK)-based in vivo PET imaging of T cell immunotherapies

Imaging TECHNOLOGY: PET T cells engineered to express a PET imaging reporter could help monitor tumor infiltration of chimeric antigen receptor (CAR) and other T cell immunotherapies. Cells expressing a triple mutant of human DCK phosphorylate and...
Read More
07:00 , Apr 14, 2014 |  BioCentury  |  Finance

Double vision

Double vision Sofinnova Ventures led NuCana BioMed Ltd.'s $57 million B round in the hopes its founders can once again bring a nucleoside-based cancer therapy to market. NuCana's ProTide technology adds a phosphoramidate moiety to oncologic nucleosides...
Read More
07:00 , Apr 3, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphocytic leukemia (ALL) Deoxycytidine kinase (DCK) In vitro and mouse studies suggest simultaneously inhibiting two deoxycytidine...
Read More
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Deoxycytidine kinase (DCK) Mouse and in vitro studies identified DCK inhibitors that could help treat cancer....
Read More
08:00 , Dec 22, 2003 |  BioCentury  |  Product Development

Around the circle

Until recently, Cyclacel Ltd. has disclosed its clinical pipeline piece by piece, which can make it hard to see how the company's overall development strategy fits together. But Cyclacel's approach to exploiting the cell cycle...
Read More